IMIbragim Gasanovich Musapirov

Ibragim Gasanovich Musapirov

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ibragim Gasanovich Musapirov has a total of 21 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Tumor microenvironment of soft tissue sarcomas: emerging opportunities for prognosis and therapy

    by D. R. Makhachev, D. V. Bulanov, R. A. Abramenko, A. R. Gasanov, M. O. Abakarov, A. D. Sanjigoryaeva, A. S. Timryazanskiy, S. A. M, A. V. Uyutnova, I. G. Musapirov, et al.

    Soft tissue sarcomas (STS) are a heterogeneous group of mesenchymal malignancies comprising over 50 histological subtypes. Despite their rarity, these tumors are characterized by aggressive clinical behavior, high metastatic potential, and limited sensitivity to conventional systemic therapies. Accumulating evidence highlights the pivotal role of the tumor microenvironment in STS progression, prognosis, and treatment response. The composition of the immune infiltrate – including tumor-associated macrophages, T and B lymphocytes, and tertiary lymphoid structures – varies substantially across histological subtypes and determines both tumor biology and susceptibility to immunotherapy. The discovery of the prognostic and predictive significance of tertiary lymphoid structures and B-cell infiltration in STS has been one of the most important advances in the field. Immune checkpoint inhibitors have shown clinical activity in select subtypes, including undifferentiated pleomorphic sarcoma, angiosarcoma, and alveolar soft part sarcoma, although overall response rates remain modest. Combination strategies integrating immune checkpoint inhibitors with antiangiogenic agents, chemotherapy, or radiation therapy, as well as adoptive cellular therapies using engineered T-cell receptors, are opening new avenues for personalized treatment. This review systematizes current knowledge on the cellular and molecular composition of the STS microenvironment, its prognostic significance, and emerging therapeutic opportunities.

  • Pathomorphological Aspects of Sarcopenia in Degenerative Spine Diseases: From Muscle Biopsy to Surgical Outcome Prediction

    by Dmitriy Vladimirovich Bulanov, Ilya Sergeevich Morozov, Anton Gerasimovich Nazarenko, Marchel Stepanovich Vetrile, Alexander Alekseevich Kuleshov, Dalgat Makhachev, Ibragim Gasanovich Musapirov, Aslakhan Vetenovich Alirzaev, Rafiga Alieva, Madina Rashidovna Musaeva, et al.

    Sarcopenia in degenerative spine diseases is a key modifiable factor influencing surgical outcomes, complication rates, and the trajectory of postoperative recovery. The paraspinal muscles—particularly the multifidus and erector spinae—play a central role in segmental stabilization and sagittal balance, making their degeneration clinically significant. This review summarizes the pathomorphological features of local sarcopenia, including predominant type II fiber atrophy, myosteatosis, endo- and perimysial fibrosis, denervation–reinnervation changes, reduced capillary density, mitochondrial dysfunction, and impaired proteostasis, all of which contribute to persistent metabolic stress within the muscle tissue. These alterations are reflected in quantitative imaging biomarkers such as proton density fat fraction (PDFF) and multi-echo Dixon sequences, cross-sectional area (CSA/lean-CSA), psoas muscle and multifidus indices (PMI/MFI), as well as CT-based measures of lumbar and paraspinal muscle density. The review discusses the integration of biopsy-derived morphological data with quantitative MRI/CT for noninvasive risk stratification and longitudinal monitoring of “muscle quality” both at the planned levels of fixation and at the upper instrumented vertebra (UIV). Particular attention is given to the association between paraspinal sarcopenia and key surgical complications, including proximal junctional kyphosis/failure (PJK/PJF), cage subsidence, construct instability, delayed rehabilitation, and an increased likelihood of revision surgery. The concept of the “muscle–bone axis,” which links paraspinal muscle status to bone mineral density and microarchitecture, is also examined due to its relevance for selecting fixation levels and implant types. Additional focus is placed on the standardization of quantitative MRI protocols, the use of validated visual grading scales when PDFF/Dixon is not available, and the role of preoperative optimization (nutritional support, correction of deficiencies, resistance training) in mitigating surgical risk. Overall, local sarcopenia is presented as a critical morpho-imaging biomarker that should be systematically incorporated into preoperative planning and postoperative rehabilitation pathways for patients with degenerative spine disorders.

  • Hormone replacement therapy in andrology: current approaches, effectiveness, and risks

    by D. R. Makhachev, I. G. Musapirov, M. N. Magomedova, M. O. Abakarov, D. M. Ametov

    This article discusses current approaches to hormone replacement therapy (HRT) in andrology, its effectiveness, and potential risks. Testosterone replacement therapy (TRT) is used to treat age-related hypogonadism and to improve the physical, cognitive, and psycho-emotional status of men. Various therapeutic formulations, including injectable and transdermal systems, their effects on patients’ health, and their limitations are analyzed. Particular attention is paid to cardiovascular complications, erythrocytosis, and safety issues associated with long-term use. Promising research directions are presented, including individualized therapy and alternative treatment modalities.

  • Artificial intelligence in diabetology: systematizing clinical evidence and prospects for implementation

    by D. R. Makhachev, I. G. Musapirov, M. N. Magomedova, M. O. Abakarov, D. M. Ametov

    Artificial intelligence (AI) is rapidly transforming the management of diabetes mellitus, extending far beyond traditional glucose monitoring. This review synthesizes clinical evidence evaluating the effectiveness of AI-driven algorithms across key domains of diabetology: screening for vascular complications, prediction of postprandial glycemic excursions, automation of insulin therapy, remote monitoring, and behavioral support. Emerging direc- tions include the integration of psychobehavioral data, reinforcement learning approaches, molecular markers, and population-level forecasting. Critical determinants of large-scale implementation are examined, including data quality, the need for multicenter validation, and the legal and ethical considerations underpinning clinical adoption.